Endoscopic band ligation for weight loss
NCT ID NCT04431232
First seen Sep 10, 2026 · Last updated Sep 10, 2026
Summary
To the best of our knowledge, this is the first study to use endoscopic band ligation for weight loss. All ligatures will be performed in the gastric body starting at the distal body; 5 parallel rows, with the last one in the proximal body.The entire procedure can be completed in 30 min. Oxygen is used for endoscopic air insufflation.Endoscopy is performed using propofol for sedation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 5 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2020
- Expected to finish
-
Jan 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * BMI \> 27 Exclusion Criteria: * Any contraindication for endoscopy * Any gastric bleeding lesions * Uncontrolled use of anticoagulants or NSAID's
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
El Katib Hospital (Celopatra Group)
RECRUITINGGiza, Dokki, 12311, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A multicenter, randomized, Active-Controlled, Open-Label phase IIb study evaluating safety and tolerability of switching to zovaglutide injection after titration to 2.4 mg semaglutide injection (Wegovy®) in adults with obesity (HORIZON-SWITCH-SZ)
- Gonadotropin-releasing hormone agonist (GnRHa) plus letrozole in obese progestin-insensitive early-stage endometrial cancer patients with conservative treatment
- Safety and feasibility of the ENDOPLY system in humans: a pilot study
- Dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like Peptide-1 (GLP-1) receptor agonist in women with obesity for frozen embryo transfer (FET): pragmatic, multicenter, randomized controlled trial
- Effects of very low calorie ketogenic diet on microbiota, adipose tissue and immunitary regulation: pilot study on patients with metabolic syndrome
- Susceptibility to infectious diseases in obesity: an endocrine, translational, sociological evaluation